Endonovo Therapeutics (ENDV) Liabilities and Shareholders Equity (2016 - 2023)
Endonovo Therapeutics has reported Liabilities and Shareholders Equity over the past 13 years, most recently at $815764.0 for Q3 2023.
- Quarterly results put Liabilities and Shareholders Equity at $815764.0 for Q3 2023, down 43.79% from a year ago — trailing twelve months through Sep 2023 was $4.3 million (down 37.24% YoY), and the annual figure for FY2022 was $1.3 million, down 36.17%.
- Liabilities and Shareholders Equity for Q3 2023 was $815764.0 at Endonovo Therapeutics, down from $1.0 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for ENDV hit a ceiling of $4.1 million in Q2 2019 and a floor of $815764.0 in Q3 2023.
- Median Liabilities and Shareholders Equity over the past 5 years was $2.3 million (2021), compared with a mean of $2.3 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: decreased 3.77% in 2019 and later tumbled 43.79% in 2023.
- Endonovo Therapeutics' Liabilities and Shareholders Equity stood at $3.3 million in 2019, then decreased by 20.39% to $2.6 million in 2020, then dropped by 23.01% to $2.0 million in 2021, then tumbled by 36.17% to $1.3 million in 2022, then tumbled by 36.33% to $815764.0 in 2023.
- The last three reported values for Liabilities and Shareholders Equity were $815764.0 (Q3 2023), $1.0 million (Q2 2023), and $1.2 million (Q1 2023) per Business Quant data.